INDUSTRY PROFILE

Indian Pharmaceutical Industry: An Overview The Indian pharmaceutical industry is a success story providing employment for millions and ensuring that essential drugs at affordable prices are available to the vast population of this sub-continent. Richard Gerster The Indian Pharmaceutical Industry today is in the front rank of Indias sciencebased industries with wide ranging capabilities in the complex field of drug manufacture and technology. A highly organized sector, the Indian Pharma Industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually. It ranks very high in the third world, in terms of technology, quality and range of medicines manufactured. From simple headache pills to sophisticated antibiotics and complex cardiac compounds, almost every type of medicine is now made indigenously. Playing a key Indian Pharma role in promoting and sustaining development in the vital field of medicines, Industry boasts of quality producers and many units approved by regulatory authorities in USA and UK. International companies associated with this sector have stimulated, assisted and spearheaded this dynamic development in the past 53 years and helped to put India on the pharmaceutical map of the world.

The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units. It has expanded drastically in the last two decades. The leading 250 pharmaceutical companies control 70% of the market with market leader holding nearly 7% of the market share. It is an extremely fragmented market with severe price competition and government price control.

The pharmaceutical industry in India meets around 70% of the country's demand for bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and injectibles. There are about 250 large units and about 8000 Small Scale Units, which form the core of the pharmaceutical industry in India (including 5 Central Public Sector Units). These units produce the complete range of pharmaceutical formulations, i.e., medicines ready for consumption by patients and about 350 bulk drugs, i.e., chemicals having therapeutic value and used for production of pharmaceutical formulations.

Following the de-licensing of the pharmaceutical industry, industrial licensing for most of the drugs and pharmaceutical products has been done away with. Manufacturers are free to produce any drug duly approved by the Drug Control Authority. Technologically strong and totally self-reliant, the pharmaceutical industry in India has low costs of production, low R&D costs, innovative

scientific manpower, strength of national laboratories and an increasing balance of trade. The Pharmaceutical Industry, with its rich scientific talents and Intellectual Property Protection regime

research capabilities, supported by

is well set to take on the international market.

ADVANTAGE-INDIA Competent workforce: India has a pool of personnel with high managerial and technical competence as also skilled workforce. It has an educated work force and English is commonly used. Professional services are easily available. Cost-effective chemical synthesis: Its track record of development, particularly in the area of improved cost-beneficial chemical synthesis for various drug molecules is excellent. It provides a wide variety of bulk drugs and exports sophisticated bulk

drugs. Legal & Financial Framework: India has a 53 year old democracy and hence has a solid legal framework and strong financial markets. There is already an established international industry and business community.

Information & Technology: It has a good network of world-class educational institutions and established strengths in Information Technology.

Globalisation: The country is committed to a free market economy and globalization. Above all, it has a 70 million middle class market, which is continuously growing. Consolidation: For the first time in many years, the international pharmaceutical industry is finding great opportunities in India. The process of consolidation, which has become a generalized phenomenon in the world pharmaceutical industry, has started taking place in India.

GROWTH-SCENARIO India's US$ 3.1 billion pharmaceutical industry is growing at the rate of 14 percent per year. It is one of the largest and most advanced among the developing countries. Over 20,000 registered pharmaceutical manufacturers exist in the country. The domestic pharmaceuticals industry output is expected to exceed Rs260 billion in the financial year 2002, which accounts for merely 1.3% of the global pharmaceutical sector. Of this, bulk drugs will account for Rs 54 bn (21%) and formulations, the remaining Rs 210 bn (79%). In financial year 2001, imports were Rs 20 bn while exports were Rs87 bn.

STEPS TO STRENGTHEN THE INDUSTRY

Indian companies need to attain the right product-mix for sustained future growth. Core competencies will play an important role in determining the future of many Indian pharmaceutical companies in the post product-patent regime after 2005. Indian companies, in an effort to consolidate their position, will have to increasingly look at merger and acquisition options of either companies or products. This would help them to offset loss of new product options, improve their R&D efforts and improve distribution to penetrate markets.

Research and development has always taken the back seat amongst Indian pharmaceutical companies. In order to stay competitive in the future, Indian companies will have to refocus and invest heavily in R&D.

The Indian pharmaceutical industry also needs to take advantage of the recent advances in biotechnology and information technology. The future of the industry will be determined by how well it markets its products to several regions and distributes risks, its forward and backward integration capabilities, its R&D, its consolidation through mergers and acquisitions, co-marketing and licensing agreements.

COMPANY PROFILE
UNIMARCK PHARMA - One of the most reputed pharmaceutical companies of Northern India, has established itself as a highly quality conscious professional organization.

UNIMARCK PHARMA has delivered results on all fronts because of its meticulous planning and marketing over the last 25 years. Unimarck Pharma is ISO 9001-2000 certified company with WHO-GMP compliance manufacturing units. It has nine sections and is manufacturing more than 400 products. It is one of the fastest growing companies of India. UNIMARCK PHARMA one of the most reputed pharmaceutical companies of Northern India, has established itself as a highly quality conscious professional organizationMr. B.P.S. Bhatia, Chairman-cum-Managing Director, is an entrepreneur with great vision. He made modest beginning in 1984 after gaining 16 years marketing experience from Pharma companies like E-Merck (I) Limited, Unique Pharmaceutical & Ranbaxy Labs in Marketing. Today, the company has created a strong base in its area of operations with a marketing field force of around 350 personnel.

Company has two state-of-the-art production units at BADDI in Himachal Pradesh conforming to G.M.P.,Schedule M and ISO 9001 specifications.

Unit I has facility to manufacture small volume parenteral (injectables), Ointments, Creams and Lotions.

Unit II has facility to manufacture Tablets, Capsules & Oral Liquid Formulations. Unimarck Group has two Divisions with separate Marketing teams under the banner of a) UNIMARCK PHARMA (INDIA) LIMITED b) ALTIUS PHARMACEUTICALS

Unimarck Group is geared up to face the challenges of World Trade Organization (WTO) norms implementation in India. Its units have huge capacity to produce various formulations which are widely accepted by the Medical fraternity. The Company is also in a process of strengthening its product portfolio. Strategic partners are being scouted from across the world for innovative products. Unimarck Pharmas focus segments are DERMATOLOGY, ORTHOPEDICS, PHYSICIAN, GYNAECOLOGY, PAEDIATRICS & DENTAL products We shall pursue world class standards in our team & products. To continually strive to be recognized as reliable source of health care Products To become the most admired pharma company in India Inculcating high performance culture

MISSION:To be a leading pharmaceutical company.

Core Values:

In Unimarck, Business practice & social commitments go hand in hand. These are values which are globally accepted & appreciated. These core values are integral to our business associates, our employees, & society.

Imaginative - Dare to be different

Passionate - Never give up

Responsible - Do the right

Excellence - Deliver the best possible

PRODUCTS PRODUCT ADMARK GEL AMBULAX TAB AMBULAX-M TAB AMBULAX HD TAB AMBULAX-FM TAB AVITIN-7 TAB COMPOSITION Adapalene 0.1% Propranolol 20 mg + Alprazolam 0.25 mg Propranolol 10 mg + Alprazolam 0.25 mg Propranolol 20 mg + Alprazolam 0.125 mg Flupenthixol 0.5 mg + Melitracen 10 mg Nettle Leaf Extract 50 mg + Saw Palmato extract 10 mg + Biotin 10 mg + Calcium Pantothenate 100 mg + Zinc 25 mg + Folic Acid 750 mcg + Selenium 65 mcg + Copper 2 mg + Manganese 5 mg + Inositol 5 mg + LLysine 10 mg + PABA 50 mg COZYMIN TAB Phenylephrine 5 mg + Cetirizine Dihydrochloride 5 mg + Paracetamol 500 mg COZYMIN SYRUP Each 5ml contains: Paracetamol 125 mg + Phenylephrine Hydrochloride 5 mg + Chlorpheniramine Maleate 1 mg + Sodium Citrate 60 mg + Menthol 1mg COZYMIN DROPS Each 1ml contains: Paracetamol 125 mg + Phenylepherine HCL 2.5 mg + Chlorpheniramine Maleate 1 mg COZYMIN-DX SYRUP Each 5 ml. contains: Dextromethorphan HBr I.P. 15 mg + Chlorpheniramine Maleate I.P. 2 mg + Phenylepherine Hcl I.P. 5 mg CROTEC EC CAPSULE Lycopene 5000 mcg + D-Salina Extract containing mixed natural Carotenoids 2.5mg + Vitamin A 2500 I.U.

+ Alpha-Tocopherol Acetate 10 I.U. + Vitamin-C 50mg + Zinc Methionine 15 mg + L-Selenomethionine 50 mcg CROTEC-EC SYRUP Each 10 ml. contains : Lycopene 5000 mcg + Vitamin A concentrate (as Palmitate) 2500 I.U + VitaminE Acetate 10 I.U. + Vitamin-C- 50mg + Selenium - 35 mcg + Zinc 3 mg + Manganese 2 mg + Iodine -100 mcg + Copper - 500mcg + Vitamin B1 - 2 mg + Vitamin B2 - 3 mg + Vitamin B6 1.5 mg CLIN-3 GEL CLIN-3 Clindamycn 1% + Nicotinamide 4% + Aloe-Allantoin MEDICATED Triclosan 0.5% + Zinc Oxide 0.5% + Allantoin 0.25% + Vitamin E (acetate) 0.25% + Tea tree Oil 0.5% Clindamycin 1% + Adapalene 0.1 % Carbonyl Iron 100 mg + Folic Acid 1.5 mg + Vitamin C 75 mg + Zinc 61.8 mg + Selenium 80 mcg + Vitamin B12 5 mcg + Vitamin E 15 I.U PART Each 1.5 ml contains : Vitamin C 150 mg I water for injection I.P. q.s. PART Each ml contains : Vitamin B12-1500 mcg + II Folic Acid 0.7 mg + Niacinamide 12 mg water for injection I.P. q.s. KALZIN-C TAB Calcitriol 0.25 mcg + Calcium Carbonate 500 mg Equi. to elemental Calcium 200 mg + Zinc KALZIN 3L INJECTION Cholecalciferol 300000 I.U.

CLEANSING BAR CLIN-AD GEL FEZEC CAP

FOLCIN-12 INJECTION

KALZIN 6L INJECTION KLORYL CREAM KLORYL-G CREAM

Cholecalciferol 600000 I.U. Clobetasol Propionate 0.05% Clobetasol Propionate 0.05% + Gentamycin Sulphate 0.1%

KLORYL-M CREAM

Clobetasol Propionate 0.05% + Miconazole Nitrate 2 %

KLORYL-S CREAM

Clobetasol Propionate 0.05% + Salicylic Acid 6%

MELANORM CREAM MELANORM HC MELANORM HC FORTE MELANORM 2

Hydroquinone 4% Hydroquinone 2% + Hydrocortisone Acetate 1% + Tretinoin 0.025% Hydroquinone 2% + Hydrocortisone Acetate 1% + Tretinoin 0.05% Hydroquinone 2% + Oxybenzone 3% + Octinoxate 5%

MELANORM-4 MELANORM MS

Hydroquinone 4% + Oxybenzone 3% + Octinoxate 5% Hydroquinone 2% + Tretinoin 0.025% + Mometasone 0.1%

MERISPAS TAB

Dicyclomine Hcl 20 mg + Mefenamic Acid 250 mg

MERISPAS SUSP

MethylPoly Siloxane 40 mg +Citric Acid Monohydrate 8 mg + Papain 6mg + Cinnamon Oil 0.0024 ml + Dill Oil 0.005 ml + Fennel Oil 0.0007 ml

MERISPAS INJECTION

Drotaverine HCL 40 mg per 2 ml

NERVIC 1500 TAB NERVIC+ INJECTION

Mecobalamin - 1500 mcg Each 2 ml. contains:

NERVIC-G TAB

Mecobalamine 500 mcg + Gabapentin 300 mg

NERVIC SYRUP

Each 5 ml. contains: Methylcobalamin 500 mcg + Thiamine Hydrochloride 10 mg + Pyridoxine

Hydrochloride 3 mg + D- panthenol 5 mg + Lysine Hydrochloride 150 mg NERVIC CAP Methylcobalamin 750 mcg + Alpha Lipoic Acid 100 mg + Benfothiamine 7.5 mg + Riboflavine 5 mg + Pyridoxine

Hydrochloride 1.5 mg + Nicotinamide 10 mg + Folic Acid 0.75 mg + Calcium Pantothenate 10 mg NERVIC P CAP NERVIC PLUS TABLET Pregabalin 75 mg + Methylcobalamin 750 mcg Pomegranate extract 40mg + Citrus Bioflavanoids 20 mg + Pine Bark Extract 10 mg + Vitamin-C 40 mg + Vitamin- B3 16 mg + Vitamin- E 15 mg + Inositol 5 mg + VitaminB5 5 mg + Vitamin- B6 2 mg + Vitamin- B2 1.4 mg + Vitamin- B1 1.2 mg + Vitamin - A 600 mcg + Folic Acid 100 mcg +

Methylcobalamin 1 mcg + Zinc Oxide eqv. To Elemental Zinc 10 mg + Magnesium ( as Magnesium Sulphate monohydrate) 5 mg + Manganese Chloride eqv. To Elemental Manganese 2 mg + Silicon ( as silicone dioxide) 2 mg + Copper Gluconate eqv. To Elemental Copper 0.9 mg + Molybdenum ( as Sod. Molybdate) 0.5 mg + Sodium Selenate eqv. To elemental Selenium 55 mcg + Chromium (as Chromium Picolinate) 65 mcg + Nickel (as nickel Sulphate) 50 mcg + Iodine ( as Pot. Iodide) 50 mcg + Vanadium ( as Sod. Vanadate) 10 mcg OKS 200 TAB OKS SUSP OKS OZ TAB OXYMARK TAB Ofloxacin 200 mg Each 5 ml. contains: Ofloxacin 50 mg Ofloxacin 200 mg + Ornidazole 500mg Dextropropoxyphene 32.5 mg + Paracetamol 400 mg + Nimusulide 100 mg PEPMARK TAB PEPMARK-D TAB Pantoprazole Sodium Sesquihydrate 40 mg Pantoprazole Sodium Sesquihydrate 20 mg + Domperidone 10 mg PEPMARK-SRD CAP Pantoprazole Sodium Sesquihydrate 40 mg (enteric coated) + Domperidone 30 mg (10 mg IR + 20 mg SR) PROPEG 100 inj. PROPEG 200 inj. Natural Micronised Progeserone 100 mg Natural Micronised Progesterone 200 mg

PROTOMARK25 Inj. PROTOMARK 50 Inj. SERECON TAB

Nandrolone Decanoate 25 mg Nandrolone Decanoate 50 mg Clidinium Bromide 2.5 mg +

Chlordiazepoxide 5 mg SERECON-D TAB Clidinium Bromide 2.5 mg +

Chlordizepoxide 5 mg + Dicyclomine Hcl 10 mg

MANUFACTURING

We manufacture and supply a wide assortment of pharmaceutical products that help in curing various diseases and improving immunity of the body. Formulated using best quality chemicals and salts with active ingredients, our range is highly effective and safe in use. We also specialize in producing various food supplements that complete the need of a balanced diet. Entire range of our products is manufactured and packed under the strict vigil of our professional to assure best quality and lengthen shelf life.

Our range encompasses:

Injectables Ointments Capsules, Oral Liquid Syrups Food supplements

CONTRACT MANUFACTURING We also undertake Contract Manufacturing on behalf of various companies located all over the country. We ensure quality standards at most affordable prices.

OUR MANUFACTURING FACILITIES Unit I - Small Volume Parenteral (Injectables), Ointments, Creams & Lotions Unit II We have two sophisticated manufacturing plants located at Baddi, 50 kms from Chandigarh which are equipped with all requisite production facilities. Small volume parenteral (injectables) and all types of ointments are manufactured in one of our production unit as per c-GMP standards.

Our second plant is Oral dosage plant where tablets, capsules, Oral Liquid Syrups/Suspension & Food supplements are manufactured. This plant meets the cGMP / WHO Standards.

We adhere to the latest regulatory guidelines while manufacturing our range of pharmaceutical Drugs & Medicines. All our products are manufactured in the hygienic environment. For better production purposes, our manufacturing unit is equipped with latest machinery which is operated by our skilled work force.

The machines that are installed in our production unit are listed below:

Ointment Manufacturing unit - Automatic DHS Autoclove Filling Machines Packaging Accessories Mixers Dryers

Blenders Rotary Machines Coaters Alu- Alu / Blister Machines Syrups Manufacturing unit Automatic Visual inspection Machines

OUR TEAM We have a team of expert professionals who have rich domain experience in this domain. Our professionals are selected on the basis of their qualification and industry experience, and we check the background of all our employees, before employing them in our organization.

In our team we have the following professionals

Medicine experts Quality controllers Chemical experts Skilled workers Research & Development expert

These professionals work in coordinated effort towards delivering best quality of Pharma products. Moreover, frequent training sessions are conducted to keep our professionals abreast with the development in the medical sector.

QUALITY ASSURANCE:

We are a quality conscious organization and focus our attention in delivering better quality of products to our clients. Our range of Pharma products is manufactured by using superior quality of material which are procured from reputed vendors. We are aware about the sensitivity attached with medicine and other Pharma products, so we undertake stringent quality checks of our products, before delivering to our clients. Right from the procurement of raw material till the final packaging, our products undergo various quality checks. Our quality Control Deptt. ensures that total quality management system is executed to maintain the standard of our products.

The various tests which are conducted by our Quality Control Deptt. are listed below:

Purity Effectiveness Toxicity Composition

Owing to such kind of strict measures, we have acquired ISO 9001-2000 & GMP certifications.

RESEARCH & DEVELOPMENT We have a sophisticated research & development wing, backed by a diligent team of R&D experts. Our experts undertake several research activities to enhance the quality and effectiveness of our range of Pharma products. Such kind of research is conducted on the basis of certain well defined parameters

CIPLA
company profile

Indias second largest pharmaceutical firm Cipla Ltd, edged out the multinational giant GlaxoSmithKline which was reigning supreme in the country for long, in terms of drug sales last year.

Consistently maintaining a fast-track growth momentum, Cipla has registered an 80-percent jump in net profit for the quarter ended on March 31 2006, driven by growth in domestic sales and exports.

In the fourth quarter, Cipla posted a net profit of 1.90 billion rupees. Net sales grew 63 percent to 8.7 billion rupees. Cipla's exports in the quarter grew 63.7 percent while domestic sales rose 56.4 percent. Cipla anticipates 15 to 20 percent growth in this year.

Cipla Ltd.: Board of Directors

Chairman & Managing Director

Dr. Y.K. Hamied

Joint Managing Directors

Mr. M.K. Hamied Mr. Amar Lulla

Non-Executive Directors
Dr. M.K.Gujar Mr. V.C. Kotwal Dr. H.R. Manchanda Mr. S.A.A. Pinto Mr. M.R. Raghavan Mr. Ramesh Shroff

Manufacturing and R&D facilities

Mumbai Corporate Office and R& D centre for formulations

Vikhroli Manufacturing of bulk drugs & formulations (Liquid Orals, Aerosols),

Bangalore Manufacturing of bulk drugs & formulations (R&D Bulk drugs)

Approved by US FDA (for bulk drugs); WHO

Patalganga Manufacturing plant for bulk drugs & formulations (R&D Bulk drugs)

Kurkumbh Manufacturing facility for bulk drugs & formulations

(R&D Bulk drugs) Goa Manufacturing set up for formulations

Baddi, Himachal Pradesh Manufacturing of tablets & capsules, formulations

Cipla Limited: Background

Based in Indias commercial capital Mumbai, The Chemical, Industrial & Pharmaceutical Laboratories, currently Cipla was founded by Khwaja Abdul Hamied in the year 1935. K A Hameid gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorised capital of Rs 6 lakhs. Cipla started markeing its product on September 22, 1937. Today, Cipla is a leading player in anti-infective and anti-asthmatic formulations. The company also specializes in the manufacturing of steroids and hormones. Cipla manufactured ampicillin for the first time in the country in 1968. In 1983, Cipla developed two anticancer drugs, vinblastine and vincristine from the common garden plant Vincarosea in association with the National Chemical Laboratory. The company pioneered the manufacture of the antiretroviral drug, zidovudine, in technological collaboration with Indian Institute of Chemical Technology in 1993. In 1997 Cipla became the first company in the world by launching transparent Rotahaler, a dry powder inhaler device. In 1998 the company launched lamivudine, and became one of the few companies in the world to offer all three component drugs of retroviral combination therapy (zidovudine and stavudine already launched). Cipla received clearance from the Drugs Controller General of India to manufacture and market the country's first non-nucleoside reverse transcriptase inhibitor (NNRTI), nevirapine, for the treatment of AIDS.

Cipla Ltd.: R&D

Cipla's R&D division focuses on the development of new products and new drug delivery systems across a range of therapies. The company is spending over 4 per cent of its total turnover on R&D activities. It filed 55 ANDAs during 2004-05 and received approval for 11 products from US FDA. The company supplies drugs to treat over 2 lakh HIV-positive patients worldwide. The company has also been among the major suppliers of anti-malarial drugs and drugs for schistosomiasis to international markets. It has a research alliance with a Bangalore-based biotech company Avesthagen, to develop biotherapeutic products.

Mergers and acquisitions of Cipla ltd.

Cipla to buy meditabspecialties to boost API and intermediate production capacity for $28 m 25 Aug 2010. Akorn and Cipla team up in 2007 for exclusive manufacturing and supply agreement for an undisclosed inhaled drug. Ciplatalk with big pharma, Takeda mulls and number of global pharma players, including Pfizer about potential generic supply deals.

Important dates

1935-Dr K A Hamied sets up "The Chemical, Industrial and Pharmaceutical Laboratories Ltd." in a rented bungalow, at Bombay Central. 1941-As the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities for the war effort. 1952-Sets up first research division for attaining self-sufficiency in technological development. 1960-Starts operations at second plant at Vikhroli, Mumbai, producing fine chemicals with special emphasis on natural products. 1968-Cipla manufactures ampicillin for the first time in the country. 1972-Starts Agricultural Research Division at Bangalore, for scientific cultivation of medicinal plants. 1976-Cipla launches medicinal aerosols for asthma. 1980-Wins Chemexcil Award for Excellence for exports. 1982-Fourth factory begins operations at Patalganga, Maharashtra. 1984-Develops anti-cancer drugs, vinblastine and vincristine in collaboration with the National Chemical Laboratory, Pune. Wins Sir P C Ray Award for developing inhouse technology for indigenous manufacture of a number of basic drugs. 1985-US FDA approves Cipla's bulk drug manufacturing facilities. 1988-Cipla wins National Award for Successful Commercialisation of Publicly Funded R&D. 1991-Lauches etoposide, a breakthrough in cancer chemotherapy, in association with Indian Institute of Chemical Technology. The company pioneers the manufacture of the antiretroviral drug, zidovudine, in technological collaboration with Indian Institute of Chemical Technology, Hyderabad.

1994-Cipla's fifth factory begins commercial production at Kurkumbh, Maharashtra. 1997-Launches transparent Rotahaler, the world's first such dry powder inhaler device now patented by Cipla in India and abroad. The palliative cancer care centre set up by the Cipla Foundation, begins offering free services at Warje, near Pune. 1998-Launches lamivudine, becoming one of the few companies in the world to offer all three component drugs of retroviral combination therapy (zidovudine and stavudine already launched). 1999-Launches Nevirapine, antiretroviral drug, used to prevent the transmission of AIDS from mother to child. 2000-Cipla became the first company, outside the USA and Europe to launch CFCfree inhalers ten years before the deadline to phase out use of CFC in medicinal products. 2002-Four state-of-the-art manufacturing facilities set up in Goa in a record time of less than twelve months. 2003-Launches TIOVA (Tiotropium bromide), a novel inhaled, long-acting anticholinergic bronchodilator that is employed as a once-daily maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). Commissioned second phase of manufacturing operations at Goa. 2005-Set-up state-of-the-art facility for manufacture of formulations at Baddi, Himachal Pradesh. 2007-Set-up state-of-the-art facility for manufacture of formulations at Sikkim. 2010-Set up state-of-the-art facility for manufacture of formulations at Indore.

Products Cipla has the largest product basket among all the pharmaceutical players in India ranging from prescription to OTC to animal health,

besides a big kitty for active pharmaceutical ingredients (APIs) or bulk drugs.

Cipla's exports Cipla exports raw materials, intermediates, prescription drugs, OTC products and veterinary productsrugs to more than 160 countries including the U.S., and a number of countries in Europe, Africa, Australia, Latin America and the Middle East.

Recently, Cipla entered agreement with PentechPharma of USA for marketing a range of generic products for American market. Pentech is involved in developing therapies for lifestyle and quality of life conditions. This will further boost its export performance. Cipla's manufacturing facilities have been approved by: Food and Drug Administration (FDA), USA; Medicines and Healthcare products Regulatory Agency (MHRA), UK; Therapeutic Goods Administration (TGA), Australia Medicines Control Council (MCC), South Africa; National Institute of Pharmacy (NIP), Hungary; Pharamaceutical Inspection Convention (PIC), Germany; World Health Organisation (WHO); Department of Health, Canada State Institute for the Control of Drugs, Slovak Republic and ANVISA, Brazil. Cipla: Future Outlook Cipla keeps the steady momentum of growth with an overall growth of more than 57% in income from operations for the quarter ended March 2006.

Currently, we are one of the largest exporters of pharmaceutical products in India, exporting APIs and formulation products to more than 160 countries including the U.S., and a number of countries in Europe, Africa, Australia, Latin America and the Middle East. Both the international as well as the domestic business have recorded a growth of more than 56% and 63% respectively, in the last quarter. All the major segments including anti-asthmatics, cardiovascular and antibiotics/bacterials segments have shown good performance in the domestic market. In the exports markets, anti-retrovirals, anti-malarials, anti-asthmatics, anti-depressants and cardiovascular segments have performed well. As Cipla turns 70, the company is set to achieve further improvement with commissioning of its expansion projects and launching of new products. It has 140 ongoing projects with five companies in the US. It has a strategic alliance with the US generics major Watson, IVAX, Eon etc. Its alliance partners have filed 31 ANDAs and it is expected that they will filled additional 35 ANDAs in the next 12-15 months.

History of Mankind pharma Ltd. Established in 1995 with a capital of 50 lakhs, Mankind at present is a leading pharmaceutical company of India. Our Goal is to help the community to lead healthy life through two parallel objectives: formulating, developing & commercializing medicines, and delivering affordable & accessible medication that satisfy urgent medical needs. Mankind has out-performed the Indian Pharmaceutical industry by growing at the rate of 60% year after year. It is among the top 5 fastest growing Pharma companies of India as per ORGIMS. It has achieved the turnover of Rs.1650 Cr in 2010-2011. It is a fully integrated pharmaceutical company having pan India presence with a comprehensive network of 62 C&F agents & 6000 Stockists. It is ranked 8th in India as per IMS-Health 2011 and as per ORG-IMS Prescription / Doctor / Month audit of Feb.2011, it is ranked 1st in India. The strong portfolio of businesses, geographies and products provide us the strategic benefits of integration that allow it to perform best in an increasingly competitive market. It has a strong market presence in Antibiotics, Antifungal, Gastrointestinal, NSAIDs, Anthelmintics, Cardiovascular, Dermal and Erectile Dysfunction categories. Numbers of our products are at top 5 positions as per ORG-ims.

The Various Divisions and Companies under Mankind GroupDiscovery Mankind Incepted in the year 2003 as a marketing division of Mankind Pharma, today Discovery Mankind

is having a wide product range to treat diabetic metabolic disorder. It is also having products in antibiotic, GI , anti fungal & lifestyle segments. Life star Pharma Launched in the year 2005 as a group company. Life star offers comprehensive range of products in ophthalmic & dermal segment. It is also having product range in antibacterial, GI & other segments. Special Mankind Special Mankind launched in January 2007 is poised to meet OTC requirements. This division is pioneer in launching of premium category condoms, toothbrush, sanitary napkins & sweeteners. Future Mankind Future Mankind was positioned in the year 2007 to cater the growing demand of acute & chronic therapeutic segments. In Future Mankind orthopedic drugs along with GI & other specialty is comprehensively represented in line to Mankind group philosophy. Magnet Labs With purpose to cater the growing market of neuropsychological segment Mankind acquired Magnet Labs in the year 2007. It is pioneer in formulations of acute & chronic psychiatric segments. Vet Mankind The strong impact of the philosophy of Serving Life lead to the foundation of this division in the year 2007 to serve the Indian animal husbandry needs. It comprises veterinary products in Antibacterial, Nutritionals, Reproductive, NSAIDs , Digestive categories etc. Pet Mankind - Launched in 2011 to cater to the needs of the pets.

Milestones 2011 Coming up with R&D and Learning & Development Centre in NCR. 2010 1) Successfully launched OTC products like Prega News, Addiction, Unwanted-72, Don't Worry. 2) Spread the wings globally with the launch of Mankind in Sri Lanka. 3) Established State-of-Art manufacturing Unit for liquid dosages & tablets.

2008 1) Achieved 40% growth. 2) 1st rank all over INDIA as per Prescription/Doctor/Month. 3) 8th Rank as per IMS-HEALTH 4) 21 brands at No. 1 position & 14 brands at No. 2 Position as per ORG-ims & stockist Secondary Audit. 5) 53 brands in top 5 position as per ORG-ims & stockiest Secondary Audit. 2007 1) Launched Future Mankind, Special Mankind and Vet Mankind. 2) Acquired Magnet Labs Pvt. Ltd. 3) Christ capital become an investor partner. 4) Awarded "Emerging Company of the year" by Indian Express Pharma Pulse. 5) Tied up with Roche Diagnostic for the marketing of product Accu chek Go. 2006 1) Established Injectable state-of-the-art unit at Paonta sahib (HP). 2) Group Turnover surged up to Rs.512 Cr. 2005 1) Celebrated Decade of trust with medical fraternity. 2) Launched Lifestar Pharma, 3) Awarded by Indian Express Pharma Pulse for Overall Best Performance . 2007 1) Company established its operations all over India. 2) Launched new division Discovery Mankind.

Mission To deliver medicines that enable patients to live healthier, happier and more active lives. Vision-

To be the No.1 Pharma Company of India by 2015 To mark the presence in former CIS Countries, South East Asia, Africa and Latin America.

InfrastructureThe Manufacturing Units are at Paonta Sahib-HP Manufacturing Unit-1

To meet the ever increasing demand of the products, Mankind has its state-of-the-art Injectable manufacturing unit at Paonta sahib (Himachal Pradesh).The unit is designed as per the USFDA (U.S. Food and Drug Administration) guidelines. The production capacity of 60 million ampoules and 30 million vials is on a single shift basis.

Manufacturing Unit-11Is under Construction but soft gelatin capsules and liquid Syrups are manufactured here.

Manufacturing Unit-111
It is designed as per Camp. Capacity of plant is 6.0 Crore tablets / month in a single sift.Plant is made for solid dosage form only with all regulatory aspects . Currently we are manufacturing Dolokind plus tabs, Losakind group, T-98, Nobel group, Pentakind, Nurokind -G, Lipikind 10/20 and many other products are in pipeline for manufacturing

Mankind ProductsThere are many (OTC )products that are given below: (Over the Counter) 1. ANTI DANDRUFF 2. CONDOMS 3. ED DRUG 4. ORAL CONTRACEPTIVE 5. PREGNANCY DETERMINATION KIT SWEETENER 6. ADICTION DEODORANT

Animal Product
1. ANTHELMINTICS 2. ANTI-INFLAMMATORY & ANALGESICS 3. ANTIBACTERIALS 4. ANTIPROTOZOAL 5. APPETITE STIMULANT / DIGESTIVES 6. FERTILITY ENHANCER 7. HORMONES 8. NUTRITIONALS 9. UTERINE TONIC

Growth Scenario in 2010India's pharmaceutical industry is now the third largest in the world in terms of volume. Its rank is 14th in terms of value. Between September 2008 and September 2009, the total turnover of India's pharmaceuticals industry was US$ 21.04 billion. The domestic market was worth US$ 12.26 billion. This was reported by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. As per a report by IMS Health India, the Indian pharmaceutical market reached US$ 10.04 billion in size in July 2010. A highly organized sector, the Indian Pharma Industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually. Know more out this in our article on Indian Pharmaceutical Industry- Future Trends Also check out Pharmaceutical Market Trends 2010

Leading Pharmaceutical CompaniesIn the domestic market, Cipla retained its leadership position with 5.27 per cent share. Ranbaxy followed next. The highest growth was for Mankind Pharma (37.2%). Other leading companies in the Indian pharma market in 2010 are

Sun Pharma (25.7%) Abbott (25%) Zydus Cadila (24.1%) Alkem Laboratories (23.3%) Pfizer (23.6 %) GSK India (19%) Piramal Healthcare (18.6 %) Lupin (18.8 %)

Future ProspectsCharacteristics of Indian Pharmaceutical The Indian pharmaceuticals market is expected to reach US$ 55 billion in 2020 from US$ 12.6 billion in 2009. This was stated in a report title "India Pharma 2020: Propelling access and acceptance, realizing true potential" by McKinsey &

Company. In the same report, it was also mentioned that in an aggressive growth scenario, the pharma market has the further potential to reach US$ 70 billion by 2020. Due to increase in the population of high income group, there is every likelihood that they will open a potential US$ 8 billion market for multinational companies selling costly drugs by 2015. This was estimated in a report by Ernst & Young. The domestic Pharma market is estimated to touch US$ 20 billion by 2015. The healthcare market in India to reach US$ 31.59 billion by 2020. The sale of all types of pharmaceutical drugs and medicines in the country stands at US$ 9.61 billion, which is expected to reach around US$ 19.22 billion by 2012. Thus India would really become a lucrative destination for clinical trials for global giants. There was another report by RNCOS titled

"Booming Pharma Sector in India" in which it was projected that the pharmaceutical formulations industry is expected to prosper in the same manner as the pharmaceutical industry. The domestic formulations market will grow at an annual rate of around 17% in 2010-11, owing to increasing middle class population and rapid urbanization.